Related Experiment Videos
CD7+ stem cell leukemia/lymphoma. Features of a subgroup without circulating blast cells
1Third Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Cancer
|July 1, 1993
Summary
This study identifies a rare CD7+ stem cell leukemia/lymphoma originating from malignant pluripotent hematopoietic stem cells. Further research is needed to understand its clinical significance compared to other CD7+ stem cell leukemia types.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Advances in immunology have elucidated the cellular origins of hematopoietic neoplasms.
- Blast cells with a CD7+ CD4- CD8- phenotype are linked to malignant pluripotent hematopoietic stem cells.
Purpose of the Study:
- To describe three rare cases of CD7+ stem cell leukemia/lymphoma, a lymphoma type.
- To investigate the cellular origin and clinical features of this rare hematologic malignancy.
Main Methods:
- Case series analysis of three patients with non-Hodgkin lymphoma and lymphadenopathy.
- Immunophenotyping of bone marrow blast cells (CD7+ CD4- CD8-).
- Histologic examination of lymph nodes (lymphoblastic lymphoma - LBL).
- Chromosomal analysis and T-cell receptor gene rearrangement studies.
Main Results:
- All patients presented with lymphoblastic lymphoma (LBL) and bone marrow blast cells exhibiting CD7+ CD4- CD8- acute leukemia immunophenotype.
- One patient relapsed in the bone marrow with myeloid differentiation antigens, indicating potential lineage plasticity.
- Consistent abnormal karyotype and T-cell receptor gene rearrangement were observed at initial diagnosis and relapse, supporting a single pluripotent leukemic clone.
Conclusions:
- The described cases represent a rare lymphoma type of CD7+ stem cell leukemia/lymphoma.
- The findings suggest a common origin from pluripotent leukemic stem cells, with potential for myeloid differentiation upon relapse.
- Further studies are necessary to clarify the clinical significance and differentiate this entity from CD7+ stem cell leukemia/lymphoma (leukemic type) and LBL.